Skip to main content
. 2021 May 13;11:640738. doi: 10.3389/fonc.2021.640738

Table 1.

Patient demographics and MRI morphological characteristics in the study set.

Parameter All Gliomas IDH Mutation IDH Wild-Type P value
Number of Patients 176 89 87
Age 46.5 [35.0,54.0] 41.0 [33.0,49.0] 50.0 [40.0,59.0] <0.001
Sex
Female 67 (38.1) 31 (34.8) 36 (41.4) 0.460
Male 109 (61.9) 58 (65.2) 51 (58.6)
Tumor Location
Frontal lobe 89 (50.6) 56 (62.9) 33 (37.9) 0.010
Other lobes 74 (42.0) 29 (32.6) 45 (51.7)
Thalamus or brainstem 9 (5.1) 3 (3.4) 6 (6.9)
Cerebellum 4 (2.3) 1 (1.1) 3 (3.4)
Diameter
<6 cm 132 (75.0) 62 (69.7) 70 (80.5) 0.139
≥6 cm 44 (25.0) 27 (30.3) 17 (19.5)
Enhancement
Nonenhancement 63 (35.8) 53 (59.6) 10 (11.5) <0.001
Patchy enhancement 42 (23.9) 25 (28.1) 17 (19.5)
Ring enhancement 71 (40.3) 11 (12.4) 60 (69.0)
Calcification
No 152 (86.4) 68 (76.4) 84 (96.6) <0.001
Yes 24 (13.6) 21 (23.6) 3 (3.4)
Cystic Change
No 73 (41.5) 48 (53.9) 25 (28.7) 0.001
Yes 103 (58.5) 41 (46.1) 62 (71.3)
Hemorrhage
No 91 (51.7) 63 (70.8) 28 (32.2) <0.001
Yes 85 (48.3) 26 (29.2) 59 (67.8)
T2 FLAIR Mismatch
No 136 (77.3) 62 (69.7) 74 (85.1) 0.024
Yes 40 (22.7) 27 (30.3) 13 (14.9)
WHO 2016 Grade
Lower-grade Glioma 102 (58.0) 78 (88.7) 23 (26.4) <0.001
Glioblastoma 74 (42.0) 10 (11.2) 64 (73.6)

Data in parentheses are ranges, and data in brackets are interquartile ranges.

IDH, isocitrate dehydrogenase; FLAIR, fluid-attenuated inversion recovery.